8-Bromo-3-methyl-xanthine (CAS 93703-24-3): A Key Pharmaceutical Intermediate for Diabetes Treatment

Explore the essential role of this purine derivative in crafting advanced diabetes therapies.

Get a Quote & Sample

Advantages Offered

High Purity and Quality

Ensuring ≥99.0% purity, this compound guarantees consistent and reliable results in complex pharmaceutical synthesis, critical for 8-Bromo-3-methyl-xanthine applications.

Versatile Intermediate

Serves as a versatile building block for various bioactive purine drugs, including important antiviral and anti-tumor agents, showcasing its role as a key purine derivative synthesis component.

Therapeutic Impact

Directly contributes to the development of treatments for type 2 diabetes through its use in synthesizing drugs like Linagliptin, highlighting its value as a diabetes drug intermediate.

Key Applications

Pharmaceutical Synthesis

Crucial for creating active pharmaceutical ingredients (APIs), particularly in the synthesis of antidiabetic medications like Linagliptin, underscoring its role as a vital pharmaceutical intermediate.

Drug Discovery Research

Utilized in research for developing new antiviral and anti-tumor drugs, leveraging its unique purine structure for novel therapeutic agent development.

Biochemical Studies

Investigated for its potential biological activities and role in purine metabolism, contributing to a deeper understanding of cellular signaling pathways.

Fine Chemical Manufacturing

Produced as a high-quality fine chemical, meeting stringent industry standards for use in various complex organic synthesis projects.